RyeproC

Whole grain rye as a functional food for suppression of prostate cancer – elucidating the role of benzoxazinoids and other bioactive constituents

Project summary

The present project will investigate the uptake and metabolization of rye bioactive constituents in prostate tissue; elucidate the effects of a high and low benzoxazinoid diet on metabolic changes in prostate cancer; correlate between markers, clinic-pathological factors and metabolomics results; conclude on which compounds are active in the suppressive effects on prostate cancer and so provide the reasons for using whole grain rye as adjuvant to the medicinal treatment of prostate cancer.  

Management

The RyeproC project (“Whole grain rye as a functional food for suppression of prostate cancer – elucidating the role of benzoxazinoids and other bioactive constituents”) is coordinated by associate professor, PhD Inge S. Fomsgaard, Aarhus University, Dept. of Agroecology.

The research work is distributed in two work packages as listed below (Acronym of participating researcher in parenthesis, bold text: principal).

WP1. Elucidation of chemical structures

Structural elucidation of whole grain rye bioactive constituents in human prostate tissue (IFO, SKS, MIB, MEB), search for specific prostate tissue metabolization products (SKS, IFO), synthesis of identified compounds (SKS, IFO).

WP2.  Effect of intake of whole grain rye food products on prostate cancer
Intervention study and sampling of prostate biopsies (MIB, MEB, SØH), elucidation of molecular reactions (SØH, MIB, scholar), metabolic profiling of primary and secondary metabolites (SKS, MIB, IFO), advanced statistical correlation (MIB, SØH, SKS, IFO, MEB).

Project coordinator

PURE error
The PURE server is currently down.

Related projects

BREAD AND BREAKFAST (Exploiting newly discovered multiple-effect bioactive compounds for the development of immunoregulatory and appetite-controlling bread and breakfast products)
www.breadandbreakfast.nu
Financed by the Danish Strategic Research Council.

MolPros (Molecular Prediction of Prostate Cancer Risk and Aggressiveness)
www.MOLPROS.DK
Financed by Aarhus University

FATEALLCHEM (Fate and toxicity of allelochemicals (natural plant toxins) in relation to environment and consumer)
www.fateallchem.dk
EU financed FP5 project, on the ecological importance of benzoxazinoids: 

AMARANTH:FUTURE-FOOD (Adding Value to Holy Grain: Providing the Key Tools for the Exploitation of Amaranth - the Protein-rich Grain of the Aztecs
www.amaranth-future-food.net
EU financed FP6 project

Participants

Aarhus University, Department of Agroecology, 
Forsøgsvej 1, DK-4200 Slagelse, Denmark

Associate professor, PhD Inge S. Fomsgaard
inge.fomsgaard@agro.au.dk
87158212 / 22283399

Head Laboratory Technician Bente B. Laursen
benteb.laursen@agro.au.dk
87157503 / 24242956

Administrative case officer Inge Harbo
inge.harbo@au.dk
87157665

Post doc Stine Krogh Steffensen
stinek.steffensen@agro.au.dk 
22739836

Clinical nutritionist Mette Borre
mette.borre@aarhus.rm.dk
78462815 / 24625453 

Consultant Mette Skaanild
mts@skaanild.dk
21 63 77 70

Aarhus University Hospital, Department of Clinical Medicine - The Department of Urology K
Brendstrupgårdsvej 100, DK-8200 Aarhus N, Denmark  

Clinical professor, dr.med Michael Borre
borre@clin.au.dk 
78 45 26 16
29 61 27 13

Project Nurse Helene Holm Pedersen
helene.holm@skejby.rm.dk
78 45 26 38

Aarhus University Hospital, Department of  Pathology,

Noerrebrogade 44, DK-8000 Aarhus C, Denmark

Head of department, Dr. Søren Høyer
http://www.auh.dk/om-auh/afdelinger/patologisk-institut/kontakt/kontakt-Patologisk-Institut/
soren.hoyer@aarhus.rm.dk
78 46 36 93 / 29 87 18 24  

 

 

Acknowledgments

The RyeproC project is funded by The Danish Council for Independent Research – Technology and Production (12-127498).

External support is generously provided by the following companies:

Lantmännen http://lantmannen.se/

Ellegaard Göttingen Minipigs www.minipigs.dk

Cytotrack http://www.cytotrack.dk/

Participants of the RyeproC project are grateful for the funding.